These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Combined immunotherapy improves survival in metastatic melanoma. Mayor S BMJ; 2015 Jun; 350():h2993. PubMed ID: 26036979 [No Abstract] [Full Text] [Related]
45. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Stenehjem DD; Au TH; Ngorsuraches S; Ma J; Bauer H; Wanishayakorn T; Nelson RS; Pfeiffer CM; Schwartz J; Korytowsky B; Oderda G; Brixner DI Melanoma Res; 2019 Dec; 29(6):626-634. PubMed ID: 30688762 [TBL] [Abstract][Full Text] [Related]
46. Emerging strategies for the treatment of metastatic melanoma: the role of monoclonal antibodies in targeted immunotherapy. Introduction. Trinh VA; Poust J Am J Health Syst Pharm; 2008 Dec; 65(24 Suppl 9):S1-2. PubMed ID: 19052262 [No Abstract] [Full Text] [Related]
47. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Pedersen M; Andersen R; Nørgaard P; Jacobsen S; Thielsen P; Thor Straten P; Svane IM Cancer Immunol Immunother; 2014 Dec; 63(12):1341-6. PubMed ID: 25227926 [TBL] [Abstract][Full Text] [Related]
48. Role of interferon in melanoma: old hopes and new perspectives. Sanlorenzo M; Vujic I; Carnevale-Schianca F; Quaglino P; Gammaitoni L; Fierro MT; Aglietta M; Sangiolo D Expert Opin Biol Ther; 2017 Apr; 17(4):475-483. PubMed ID: 28274138 [TBL] [Abstract][Full Text] [Related]
49. Drug development: Releasing the brakes. Weintraub K Nature; 2013 Dec; 504(7480):S6-8. PubMed ID: 24352363 [No Abstract] [Full Text] [Related]
50. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. de Greef R; Elassaiss-Schaap J; Chatterjee M; Turner DC; Ahamadi M; Forman M; Cutler D; de Alwis DP; Kondic A; Stone J CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):5-7. PubMed ID: 27653180 [TBL] [Abstract][Full Text] [Related]
51. Melanoma and a Headache. Diagnosis: Hypophysitis. Johnson DB; Mudigonda TV; Sosman JA JAMA Oncol; 2015 Nov; 1(8):1167-8. PubMed ID: 26225893 [No Abstract] [Full Text] [Related]
52. Utilization of immunotherapy among patients with stage 4 melanoma: An analysis of the National Cancer Database from 2012 to 2016. Shah PV; Choi JN; Fiessinger L; Nardone B; Nguyen CV; Liszewski W J Am Acad Dermatol; 2021 Mar; 84(3):811-814. PubMed ID: 32553633 [No Abstract] [Full Text] [Related]
53. [How to choose the optimal therapy? New issues in the treatment of metastatic melanoma]. Oláh J; Gyulai R Magy Onkol; 2016 Mar; 60(1):17-21. PubMed ID: 26934346 [TBL] [Abstract][Full Text] [Related]
54. Immunotherapy and Oncogenic Pathways: The PTEN Connection. Rizvi NA; Chan TA Cancer Discov; 2016 Feb; 6(2):128-9. PubMed ID: 26851183 [TBL] [Abstract][Full Text] [Related]
55. Adoption of ipilimumab in the United States: a Medicare study. Yao N; Jang S Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):439-40. PubMed ID: 27097117 [No Abstract] [Full Text] [Related]
56. Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen. Goldstein DA JAMA Oncol; 2017 Dec; 3(12):1628-1629. PubMed ID: 28983562 [No Abstract] [Full Text] [Related]